
Annual report 2023
added 12-13-2025
Profound Medical Corp. Revenue 2011-2025 | PROF
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Profound Medical Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.2 M | 6.68 M | 6.87 M | 7.3 M | 4.17 M | 2.6 M | 4.9 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.3 M | 2.6 M | 5.68 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 96.13 | 0.04 % | $ 141 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.6 | - | $ 125 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 301.75 | 0.24 % | $ 8.51 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 48.12 | 0.21 % | $ 7.17 K | ||
|
Abbott Laboratories
ABT
|
42 B | $ 124.81 | 0.22 % | $ 217 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 2.97 | 4.58 % | $ 111 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.47 | 0.7 % | $ 1.15 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.14 | 3.64 % | $ 18.4 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 97.06 | 0.48 % | $ 1.23 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.54 | - | $ 685 M | ||
|
LivaNova PLC
LIVN
|
1.25 B | $ 63.08 | -0.27 % | $ 3.42 B | ||
|
LENSAR
LNSR
|
53.5 M | $ 12.01 | -0.08 % | $ 138 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
4 B | $ 157.84 | 0.69 % | $ 11.8 B | ||
|
NanoVibronix
NAOV
|
2.56 M | - | - | $ 1.08 M | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.86 | 0.43 % | $ 88.4 M | ||
|
Myomo
MYO
|
1 B | $ 1.02 | 12.09 % | $ 7.19 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 14.49 | 0.84 % | $ 392 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 14.53 | 0.07 % | $ 95.2 M | ||
|
AxoGen
AXGN
|
187 M | $ 32.64 | -0.61 % | $ 1.44 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 40.17 | 1.34 % | $ 1.24 B | ||
|
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | ||
|
OrthoPediatrics Corp.
KIDS
|
205 M | $ 17.41 | 0.75 % | $ 402 M | ||
|
Globus Medical
GMED
|
2.52 B | $ 88.43 | -0.38 % | $ 12 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 12.66 | 0.56 % | $ 975 M |